Immune Checkpoint Blockade Combined with AbnobaViscum<sup>®</sup> Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence

Immune Checkpoint Blockade Combined with AbnobaViscum<sup>®</sup> Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence

<b>Background:</b> Recent advancements in cancer treatment have shown the potential of immune checkpoint blockade (ICB) plus <i>Viscum album</i> L. therapy in improving survival rates for patients with advanced or metastatic non-small-cell lung cancer (NSCLC). The objective o...

Full description

Saved in:
Bibliographic Details
Main Authors: Friedemann Schad, Anja Thronicke, Ralf-Dieter Hofheinz, Reinhild Klein, Patricia Grabowski, Shiao Li Oei, Hannah Wüstefeld, Christian Grah
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Pharmaceuticals
Subjects:
PD-1 inhibitor
PD-L1 inhibitor
survival
abnobaViscum<sup>®</sup> therapy
non-small-cell lung cancer
lung cancer
Online Access:https://www.mdpi.com/1424-8247/17/12/1713
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1424-8247/17/12/1713

Similar Items